Cyclo Therapeutics (Cyclo Therapeutics) GF Value Rank : 0 (As of Apr. 27, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Cyclo Therapeutics GF Value Rank?

Cyclo Therapeutics has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Cyclo Therapeutics GF Value Rank Related Terms

Thank you for viewing the detailed overview of Cyclo Therapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclo Therapeutics (Cyclo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyclo Therapeutics Inc (NAS:CYTH) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

6714 North West 16th Street, Suite B, Gainesville, FL, USA, 32653

Website

https://www.cyclodex.com

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.

Executives

Vivien Wong	director	6C CHATEAUX CIRCLE, SCARSDALE NY 10583
Rafael Holdings, Inc.	10 percent owner	520 BROAD STREET, NEWARK NJ 07120
William Conkling	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Jeffrey Tate	director, officer: Chief Executive Officer	C/O CTD HOLDINGS, INC., 27317 NW 78TH AVENUE, HIGH SPRINGS FL 32643
Francis Patrick Ostronic	director	932 HUNGERFORD DRIVE, SUITE 28A, ROCKVILLE MD 20850
Markus Sieger	director	BEUTSTWEG 12, CH-8032, ZURICH V8 000000000
N Scott Fine	director	600 3RD AVE, NEW YORK NY 10016
Sharon Hemond Hrynkow	officer: SVP for Medical Affairs	4816 KING SOLOMON DRIVE, ANNADALE VA 22003
Lise Lund Kjems	officer: Chief Medical Officer	91 ROLLINGWOOD LN., CONCORD MA 01742
Joshua M Fine	officer: Chief Financial Officer	21 HEMMELSKAMP ROAD, WILTON CT 06897
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Michael Eric Lisjak	officer: Chief Regulatory Officer	12 ROOSEVELT AVENUE, OLD GREENWICH CT 06870
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
L.p. Novit,	10 percent owner	966 HUNGERFORD DRIVE, ROCKVILLE MD 20850